Compare CCLD & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | RLYB |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 86.6M |
| IPO Year | 2013 | 2021 |
| Metric | CCLD | RLYB |
|---|---|---|
| Price | $2.47 | $16.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 463.1K | 15.6K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.71 | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | ★ $120,499,000.00 | $858,000.00 |
| Revenue This Year | $11.49 | N/A |
| Revenue Next Year | $7.95 | N/A |
| P/E Ratio | ★ N/A | $2.73 |
| Revenue Growth | 8.72 | ★ 43.00 |
| 52 Week Low | $2.03 | $0.48 |
| 52 Week High | $3.98 | $17.57 |
| Indicator | CCLD | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 55.71 |
| Support Level | $2.07 | $16.51 |
| Resistance Level | $3.14 | $17.34 |
| Average True Range (ATR) | 0.14 | 0.47 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 27.72 | 47.32 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.